TRANSGENE
BIOTEK LIMITED
INNOVATING. FOR LIFE.

Date 07-11-2026

The General Manager
Department of Corporate Services – CRD
BSE LIMITED Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400 001.

Ref:- Scrip Code : 526139

Dear Sir/Madam,

Subject: **Intimation of the Board Meeting to be held on Friday, 13th November, 2026**

Pursuant to Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that a meeting of the Board of Directors of **Transgene Biotek Limited** is scheduled to be held on **Friday, November 13, 2026**, inter alia, to consider and approve the following matters:

1) To consider and approve the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and half yearly ended September 30, 2026.

2) To consider and approve the Limited Review Report (Standalone & Consolidated) for the quarter and half year ended on ended September 30, 2026.

3) To consider and approve the Notice of the 36th Annual General Meeting of the Company for the financial Year 2025-26 and other matters incidental thereto.

4) To consider and approve the Board's Report along with its annexures for the Financial Year 2025-26.

5) To consider and approve the Record Date, Book Closure period and e-voting dates in connection with the ensuing Annual General Meeting.

6) To appoint a Scrutinizer for conducting the e-voting process for the ensuing Annual General Meeting.

7) To consider and approve the re-appointment of Dr.K.Koteswara Rao (DIN: 07167872) as the Chairman & Managing Director of the Company for a further period of one year, subject to the approval of the shareholders.

8) To transact such other business as may be required.

Further details, as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, shall be submitted to the Stock Exchange after the conclusion of the Board Meeting, wherever applicable.

Further, we wish to inform you that as per the Code of Conduct adopted by the Company, to regulate, monitor and report trading by insiders, pursuant to the SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018, the Trading Window for dealing in the securities of the Company was already closed from 1st October, 2026 till 48 hours after the financial results of the Company for the quarter ended on 30th September, 2026 become generally available information.

We request you to kindly take the above information on record.

Thanking You,

Yours faithfully,
For TRANSGENE BIOTEK LIMITED



DR K KOTESWARA RAO
MANAGING DIRECTOR
(DIN: 07167872)

Plot 69 & 70 IDA Bollaram, Sangareddy District – 502 325, Telangana, India
Ph: +91-40-65589499 Fax: +91-8458-279755 Web: www.transgenebiotek.com
Email: info@transgenebiotek.com, CIN No: L85195TG1990PLC011065